131 related articles for article (PubMed ID: 7196561)
1. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.
Creagan ET; Eagan RT; Kvols LK
Oncology; 1981; 38(5):260-1. PubMed ID: 7196561
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.
Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK
Cancer Treat Rep; 1981; 65(5-6):517-9. PubMed ID: 7195306
[No Abstract] [Full Text] [Related]
3. Dianhydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix.
Vogl SE; Seltzer V; Camacho F; Calanog A
Cancer Treat Rep; 1982 Oct; 66(10):1809-12. PubMed ID: 6889913
[TBL] [Abstract][Full Text] [Related]
4. Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer.
Goldhirsch A; Joss RA; Cavalli F; Sonntag RW; Brunner KW
Med Pediatr Oncol; 1981; 9(3):205-8. PubMed ID: 6264280
[TBL] [Abstract][Full Text] [Related]
5. cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.
Sierocki JS; Hilaris BS; Hopfan S; Martini N; Barton D; Golbey RB; Wittes RE
Cancer Treat Rep; 1979; 63(9-10):1593-7. PubMed ID: 227598
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.
Hahn RG; Bauer M; Wolter J; Creech R; Bennett JM; Wampler G
Cancer Treat Rep; 1979 Mar; 63(3):513-5. PubMed ID: 371804
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers.
Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK
Cancer Treat Rep; 1981; 65(5-6):453-8. PubMed ID: 6263477
[TBL] [Abstract][Full Text] [Related]
8. Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD; Scott M
Cancer Treat Rep; 1982 Aug; 66(8):1647-9. PubMed ID: 7105055
[No Abstract] [Full Text] [Related]
9. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
Haas CD; Baker L; Thigpen T
Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943
[TBL] [Abstract][Full Text] [Related]
10. Combination cis-platinum and etoposide in small-cell lung cancer.
Natale RB; Wittes RE
Cancer Treat Rev; 1982 Jun; 9 Suppl():91-4. PubMed ID: 6290058
[No Abstract] [Full Text] [Related]
11. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
Perry MC; Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
[TBL] [Abstract][Full Text] [Related]
12. Treatment of inoperable non-small-cell bronchogenic carcinoma with etoposide and cis-platinum.
Mitrou PS; Fischer M; Weissenfels I; Diehl V; Gropp C; Liesenfeld A; Schmidt M; Berdel WE; Fink U; Graubner M
Cancer Treat Rev; 1982 Jun; 9 Suppl():139-42. PubMed ID: 6889919
[No Abstract] [Full Text] [Related]
13. Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.
de Jager R; Brugarolas A; Hansen H; Cavalli F; Ryssel H; Siegenthaler P; Clarysse A; Renard J; Kenis Y; Alberto P
Eur J Cancer (1965); 1979 Jul; 15(7):971-4. PubMed ID: 385328
[No Abstract] [Full Text] [Related]
14. Etoposide and cis-platinum in non-small-cell bronchogenic carcinoma.
Klastersky J; Longeval E; Nicaise C; Weerts D
Cancer Treat Rev; 1982 Jun; 9 Suppl():133-8. PubMed ID: 6889918
[No Abstract] [Full Text] [Related]
15. Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
Creagan ET; Eagan RT; Rubin J
Med Pediatr Oncol; 1979; 7(2):179-80. PubMed ID: 502975
[No Abstract] [Full Text] [Related]
16. Phase II studies of dianhydrogalactitol-based combination chemotherapy for recurrent brain tumors.
Eagan RT; Creagan ET; Bisel HF; Layton DD; Groover RV; Herman RC
Oncology; 1981; 38(1):4-6. PubMed ID: 7443176
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.
Eagan RT; Ames MM; Powis G; Kovach JS
Cancer Treat Rep; 1982 Feb; 66(2):283-7. PubMed ID: 7034934
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
[No Abstract] [Full Text] [Related]
19. VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung.
Eagan RT; Creagan ET; Ingle JN; Rubin J; Frytak S; Kvols LK; Fleming TR
Tumori; 1979 Feb; 65(1):105-9. PubMed ID: 442215
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
